Evidence map›Paper›PMID 40370553›Full record

Trial reportActa pharmaceutica Sinica. B2025

A retrospective cohort study of the efficacy and safety of oral azvudine

Bo Yu, Haiyu Wang, Guangming Li, Junyi Sun, Hong Luo, Mengzhao Yang, Yanyang Zhang, Ruihan Liu, Ming Cheng, Shixi Zhang and 8 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Bo YuDepartment of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Haiyu WangDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Guangming LiDepartment of Liver Disease, the Affiliated Infectious Disease Hospital of Zhengzhou University, Zhengzhou 450052, China.
Junyi SunDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Hong LuoGuangshan County People's Hospital, Guangshan County, Xinyang 465450, China.
Mengzhao YangDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Yanyang ZhangHenan Center for Disease Control and Prevention, Zhengzhou 450016, China.
Ruihan LiuXiangya Medical College, Central South University, Changsha 410028, China.
Ming ChengDepartment of Medical Information, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Shixi ZhangDepartment of Infectious Diseases, Shangqiu Municipal Hospital, Shangqiu 476000, China.
Guotao LiDepartment of Infectious Diseases, Luoyang Central Hospital Affiliated of Zhengzhou University, Luoyang 471000, China.
Ling WangDepartment of Clinical Laboratory, Henan Provincial Chest Hospital Affiliated of Zhengzhou University, Zhengzhou 450008, China.
Guowu QianDepartment of Gastrointestinal Surgery, Nanyang Central Hospital, Nanyang 473009, China.
Donghua ZhangDepartment of Infectious Diseases, Anyang City Fifth People's Hospital, Anyang 455000, China.
Silin LiDepartment of Respiratory and Critical Care Medicine, Fengqiu County People's Hospital, Xinxiang 453300, China.
Quancheng KanHenan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou 450052, China.
Jiandong JiangState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China.
Zhigang RenDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Azvudine and nirmatrelvir/ritonavir (Paxlovid) are recommended for COVID-19 treatment in China, but their safety and efficacy in the elderly population are not fully known. In this multicenter, retrospective, cohort study, we identified 5131 elderly hospitalized COVID-19 patients from 32,864 COVID-19 patients admitted to nine hospitals in Henan Province, China, from December 5, 2022, to January 31, 2023. The primary outcome was all-cause death, and the secondary outcome was composite disease progression. Propensity score matching (PSM) was performed to control for confounding factors, including demographics, vaccination status, comorbidities, and laboratory tests. After 2:1 PSM, 1786 elderly patients receiving azvudine and 893 elderly patients receiving Paxlovid were included. Kaplan-Meier and Cox regression analyses revealed that compared with Paxlovid group, azvudine could significantly reduce the risk of all-cause death (log-rank

Indexed as

AzvudineComparative studyCOVID-19EffectivenessElderlyPaxlovidReal-worldSafety

Identifiers

PMID40370553
PMCPMC12069234

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.